500 Results for "

auditory fear memory

" in MedChemExpress (MCE) Product Catalog:

Products (500)

Sort by :

Categories

By Targets

Products

149

SB 202190

149 Publications Verification

Cat. No.: HY-10295

CAS No.: 152121-30-7

Purity: 99.89%

Target:

Organoid p38 MAPK Autophagy Apoptosis

Research Areas:

Neurological Disease Cancer

SB 202190 is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Bucladesine sodium

55 Cited Publications

Cat. No.: HY-B0764

CAS No.: 16980-89-5

Synonyms: Dibutyryl cAMP sodium; DBcAMP sodium

Target:

PKA Reactive Oxygen Species (ROS) Apoptosis

Research Areas:

Neurological Disease Inflammation/Immunology Cancer

Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Bucladesine hemicalcium

55 Cited Publications

Cat. No.: HY-B0764A

CAS No.: 938448-87-4

Synonyms: Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium

Target:

PKA Apoptosis Reactive Oxygen Species (ROS)

Research Areas:

Neurological Disease Cancer

Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Methyllycaconitine citrate

54 Cited Publications

Cat. No.: HY-N2332A

CAS No.: 351344-10-0

Synonyms: MLA citrate

Target:

nAChR Autophagy Reactive Oxygen Species (ROS) mTOR

Research Areas:

Neurological Disease

Methyllycaconitine (MLA) citrate is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC₅₀ of 2 nM. Methyllycaconitine citrate inhibits Aβ_25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine citrate induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine citrate can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

ANA-12

43 Cited Publications

Cat. No.: HY-12497

CAS No.: 219766-25-3

Purity: 99.90%

Target:

Trk Receptor NOD-like Receptor (NLR) AIM2 Caspase

Research Areas:

Neurological Disease Inflammation/Immunology

ANA-12 is a brain-penetrant, selective TrkB antagonist with IC₅₀ values of 45.6 nM and 41.1 μM, and K_d values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

1400W

33 Cited Publications

Cat. No.: HY-18730

CAS No.: 180001-34-7

Synonyms: W1400

Target:

NO Synthase Apoptosis

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

1400W Dihydrochloride

33 Cited Publications

Cat. No.: HY-18731

CAS No.: 214358-33-5

Target:

NO Synthase Apoptosis

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

SB 239063

31 Cited Publications

Cat. No.: HY-11068

CAS No.: 193551-21-2

Purity: 99.15%

Target:

p38 MAPK Autophagy

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB) .

Compare